Free Trial

GRI Bio (GRI) Competitors

GRI Bio logo
$1.99 +0.02 (+1.02%)
As of 07/25/2025 04:00 PM Eastern

GRI vs. IXHL, RLYB, ASBP, VYNE, PASG, GELS, EDSA, BIVI, LPCN, and DRRX

Should you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include Incannex Healthcare (IXHL), Rallybio (RLYB), Aspire Biopharma (ASBP), VYNE Therapeutics (VYNE), Passage Bio (PASG), Gelteq (GELS), Edesa Biotech (EDSA), BioVie (BIVI), Lipocine (LPCN), and DURECT (DRRX). These companies are all part of the "pharmaceutical products" industry.

GRI Bio vs. Its Competitors

GRI Bio (NASDAQ:GRI) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 0.1% of GRI Bio shares are owned by insiders. Comparatively, 15.5% of Incannex Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GRI Bio currently has a consensus target price of $22.00, suggesting a potential upside of 1,005.53%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Incannex Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRI Bio
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Incannex Healthcare
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

GRI Bio has higher earnings, but lower revenue than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRI BioN/AN/A-$8.21M-$11.56-0.17
Incannex Healthcare$10K3,090.15-$18.46M-$1.21-0.87

In the previous week, Incannex Healthcare had 4 more articles in the media than GRI Bio. MarketBeat recorded 7 mentions for Incannex Healthcare and 3 mentions for GRI Bio. GRI Bio's average media sentiment score of 0.63 beat Incannex Healthcare's score of 0.37 indicating that GRI Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GRI Bio
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Incannex Healthcare
0 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

GRI Bio's return on equity of -275.15% beat Incannex Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
GRI BioN/A -275.15% -168.22%
Incannex Healthcare N/A -342.92%-148.64%

GRI Bio has a beta of -1.62, suggesting that its share price is 262% less volatile than the S&P 500. Comparatively, Incannex Healthcare has a beta of 7.47, suggesting that its share price is 647% more volatile than the S&P 500.

Summary

GRI Bio beats Incannex Healthcare on 8 of the 14 factors compared between the two stocks.

Get GRI Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRI vs. The Competition

MetricGRI BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.92M$3.06B$5.69B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E Ratio-0.1721.1828.1020.05
Price / SalesN/A288.50432.4490.07
Price / CashN/A42.7636.2258.56
Price / Book0.268.378.665.87
Net Income-$8.21M-$55.19M$3.25B$258.55M
7 Day Performance9.34%5.88%4.23%3.74%
1 Month Performance55.47%17.33%10.52%11.75%
1 Year Performance-90.71%4.42%34.41%18.03%

GRI Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRI
GRI Bio
2.9111 of 5 stars
$1.99
+1.0%
$22.00
+1,005.5%
-90.8%$4.92MN/A-0.171
IXHL
Incannex Healthcare
0.7438 of 5 stars
$0.82
+34.4%
N/A-51.4%$17.95M$10K-0.683News Coverage
Gap Down
High Trading Volume
RLYB
Rallybio
2.872 of 5 stars
$0.46
+7.5%
$10.00
+2,063.1%
-62.5%$17.89M$640K-0.4240Positive News
ASBP
Aspire Biopharma
N/A$0.41
+14.1%
N/AN/A$17.73MN/A0.00N/ANews Coverage
Analyst Downgrade
Gap Down
VYNE
VYNE Therapeutics
2.9385 of 5 stars
$1.21
+4.3%
$6.25
+416.5%
-30.5%$17.64M$500K-1.2230High Trading Volume
PASG
Passage Bio
3.3868 of 5 stars
$5.27
-5.2%
$150.00
+2,746.3%
-57.7%$17.35MN/A-0.26130News Coverage
Positive News
Insider Trade
Gap Up
High Trading Volume
GELS
Gelteq
N/A$1.83
+0.5%
N/AN/A$17.18M$100K0.00N/AGap Up
EDSA
Edesa Biotech
2.3532 of 5 stars
$2.41
+0.4%
$5.00
+107.5%
-53.2%$16.85MN/A-1.5220Positive News
BIVI
BioVie
0.7623 of 5 stars
$7.31
-18.7%
N/A+69.0%$16.73MN/A-0.0910News Coverage
LPCN
Lipocine
2.8716 of 5 stars
$3.17
+1.6%
$9.00
+183.9%
-40.9%$16.67M$11.20M-3.1110
DRRX
DURECT
1.1933 of 5 stars
$0.57
+5.5%
N/A-65.6%$16.62M$2.03M-3.7780Positive News
Gap Down

Related Companies and Tools


This page (NASDAQ:GRI) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners